Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus

Therapuetic Areas:Gastroenterology
Age Range:18 - 100
Start Date:May 10, 2018
End Date:November 3, 2019
Contact:Danielle Kim Turgeon, MD

Use our guide to learn which trials are right for you!

Phase I In-vivo Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus

The overall aim of this feasibility study is to develop new technologies for improved
detection of Barrett's neoplasia using the scanning fiber endoscope(SFE) multiplexed imaging
system. This study will combine the use of fluorescent-labeled peptides that bind
specifically to pre-cancerous mucosa in the esophagus for use as novel imaging agents to
guide endoscopic biopsy or endoscopic mucosal resection (EMR). This Phase 1 study will be
used to provide early evidence of efficacy for the topical application of a panel of two
peptides that bind to molecular targets that are specific for esophageal dysplasia. A panel
is needed because cancer in the esophagus is genetically heterogeneous. The study will look
at peptide binding in subjects with known or suspected Barrett's esophagus.

Inclusion Criteria:

- Known or suspected Barrett's esophagus

- Scheduled for a clinically-indicated upper endoscopy

- Medically cleared for the procedure

- Willing and able to sign informed consent

Exclusion Criteria:

- Known allergy or negative reaction to the near infrared fluorophores Cy5, li-cor
IRDye800CW, or derivatives

- One active chemotherapy or radiation treatment

- Pregnant or trying to conceive
We found this trial at
Ann Arbor, Michigan 48109
Ann Arbor, MI
Click here to add this to my saved trials